Showing results (421-430 of 431) with videos related to
Sort By:
Pageof 44
Advances in Therapy|May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.Science Translational Medicine|September 17, 2025
Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infectionHyeongki Park, Naotoshi Nakamura, Sho Miyamoto, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 16, 2013
Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenograftsLinda Scobie, Vered Padler-Karavani, Stephanie Le Bas-Bernardet, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 21, 2026
Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.Microbiology Spectrum|May 4, 2023
A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19Taiga Miyazaki, Naoki Hosogaya, Yuri Fukushige, et al.Proceedings of the National Academy of Sciences of the United States of America|December 22, 2023
Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infectionSho Miyamoto, Takara Nishiyama, Akira Ueno, et al.Calcified Tissue International|August 4, 2022
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 StudyMaria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, et al.Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.RMD Open|September 22, 2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Anthony A Portale, Maria Luisa Brandi, et al.Nature Medicine|February 18, 2022
The role of antibody responses against glycans in bioprosthetic heart valve calcification and deteriorationThomas Senage, Anu Paul, Thierry Le Tourneau, et al.Pageof 44